Hospital

Novel C. difficile infection (CDI) vaccine shows promise lowering the severity of CDI and in preventing medically attended CDI.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

Researchers found that in a program of biennial screening of women aged 50 to 74 years, approximately 1 in 7 screen-detected breast cancer cases would be overdiagnosed.

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

The proof-of-concept study is expected to announce topline safety, tolerability, and immunogenicity results by the end of 2022.

The annual conference includes presentations with educational opportunities related to community pharmacies, health system pharmacies, pharmacy law, public health, and more.

Nivolumab (Opdivo) plus platinum-doublet chemotherapy approved for the treatment of adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Aggrenox is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

Study results show that individuals hospitalized for acute heart failure are 36% more likely to experience clinical benefit over 90 days if initiated on the drug following stabilization.

The findings highlight the potential of acetaminophen, non-steroidal anti-inflammatory drugs, and opioid analgesics to treat infectious diseases.

Durvalumab plus chemotherapy did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.

Kaléo’s product has received fast-track designation for US military personnel facing this threat on the battlefield.

Durable responses mark a significant advancement over chemotherapy, which may have only been effective for 9 to 10 months.

Acceptance is based on CheckMate -816 trial results where the agency granted priority review status to the Bristol Myers Squibb drug and assigned a PDUFA goal date of July 13, 2022.

Investigators at Penn State find that these medications inhibit certain viral enzymes called proteases that are essential for SARS-CoV-2 replication in infected human cells.

COVID-19 vaccines are effective in preventing severe infection resulting in hospitalization, but protection wanes after 6 months.

New strategies are needed to increase HIV prevention and testing efforts among high-risk communities.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses why classification of gabapentin as schedule V might be beneficial.

While staffing challenges mean health leaders may have to shift priorities and resources, one area where we shouldn’t scale back is in our efforts to mitigate health care drug diversion.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how the beliefs and perceptions of cancer among adults living in rural areas compared to those of adults living in urban areas.

Filgrastim-ayow is indicated for the treatment of neutropenia, which is commonly experienced by patients receiving chemotherapy.

Although biologic changes may occur in the body that affect the brain, nonbiologic changes, such as social isolation, can also be a part of it but the reasons are not completely clear, according to the study.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how dosing for rucaparib treatment is assessed to treat patients with ovarian cancer.

At week 4, there was about a 61.6% decrease for individuals with hypercholesterolemia who do not attain low-density lipoprotein cholesterol and/or are intolerant to other lipid-lowering drugs.

During spring to fall 2020 related visits to emergency departments declined compared with a year earlier, study results show.

The agency has given the greenlight to the abbreviated new drug application for the overdose-reversal medication.

The CAR T-cell therapy CYAD-101 was being evaluated in combination with FOLFOX followed by pembrolizumab (Keytruda) in patients with unresectable metastatic colorectal cancer.

Rocuronium bromide is indicated as an adjunct to general anesthesia and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Lakyn Husinka, PharmD, discussed new treatment options and pharmacists' role in treating patients with breast cancer.

PrEP involves taking emtricitabine/tenofovir (Truvada or Descovy) to prevent high-risk individuals from contracting HIV.